RNS Number : 0186C MaxCyte, Inc. 16 June 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Publication of Annual Report and Accounts Gaithersburg, Maryland - 16 June 2021 : MaxCyte (LSE: MXCT, MXCN), a leading provider of cell-engineering platform
RNS Number : 5575A MaxCyte, Inc. 02 June 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 2 June 2021 : MaxCyte (LSE: MXCT, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block admission
RNS Number : 6449Z MaxCyte, Inc. 25 May 2021 FOR IMMEDIATE RELEASE Celularity and MaxCyte Sign Strategic Platform Licence to Advance Celularity's Off-the-shelf Allogeneic Cellular Therapy Product Candidates Celularity to utilize MaxCyte's Flow Electroporation ® technology and ExPERT ™
RNS Number : 9571V MaxCyte, Inc. 20 April 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") MaxCyte Reports Final Results for the Year Ended 31 December 2020 Gaithersburg , Maryland - 20 April 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), a leading provider of cell-engineering
RNS Number : 2232U MaxCyte, Inc. 01 April 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 April 2021 : MaxCyte (LSE: MXCT, MXCL, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block
Released : March 03, 2021 07:00 RNS Number : 9363Q MaxCyte, Inc. 03 March 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights Gaithersburg, Maryland - 3 March 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global cell-based medicines and life sciences company, announces
Released : February 19, 2021 07:00 RNS Number : 6562P MaxCyte, Inc. 19 February 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings and Issue of Equity Total Voting Rights Gaithersburg, Maryland - 19 February 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global
Released : February 17, 2021 17:44 RNS Number : 4895P MaxCyte, Inc. 17 February 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Gaithersburg, Maryland - 17 February 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global clinical-stage cell-based therapies and life sciences
Released : February 04, 2021 07:00 RNS Number : 9374N MaxCyte, Inc. 04 February 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings and Issue of Equity Gaithersburg, Maryland - 4 February 2021: MaxCyte (LSE: MXCT, MXCL), the global cell-based medicines and life sciences
Released : February 04, 2021 07:00 RNS Number : 9342N MaxCyte, Inc. 04 February 2021 GENERAL TEXT AMENDMENT The following amendment(s) have been made to the ' MaxCyte Announces £40 million Subscription' announcement released on 03/02/2021 at 16.36 under RNS No 9191N. References to "T.
